Document Detail

Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
MedLine Citation:
PMID:  17018504     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Hypercalcemia in pregnancy can have devastating effects on both mother and fetus. Pamidronate, a bisphosphonate and inhibitor of bone resorption, has been used to treat hypercalcemia, but it is considered contraindicated in pregnancy. CASE: A 40-year-old multigravida presented at 24 weeks of gestation with metastatic breast cancer. After unsuccessful chemotherapy, at 28 weeks of gestation she had deteriorating renal function, frequent contractions, and a calcium level of 17.6 mg/dL. When conventional treatment of hypercalcemia failed, pamidronate dramatically decreased both the calcium levels and the frequency of uterine contractions. CONCLUSION: Pamidronate in pregnancy successfully reduced severe maternal hypercalcemia and uterine contractions. Although the reduction in calcium level did not prevent the development of preeclampsia or further deterioration in the mother's condition, it was not associated with any adverse effects on the neonate.
Emily C Culbert; Barry S Schfirin
Related Documents :
2342734 - Pregnancy outcome of patients with uncorrected uterine anomalies managed in a high-risk...
3693154 - Effect of unilateral hysterectomy and ovariectomy on puberty, uterine size and embryo d...
16105174 - Successful myomectomy during pregnancy: a case report.
17538144 - Focal myometrial defect and partial placenta accreta in a pregnancy following bilateral...
23926514 - The role of cervical cerclage in pregnancy outcome in women with uterine anomaly.
24960174 - Amino acids in the uterine luminal fluid reflects the temporal changes in transporter e...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  108     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-10-04     Completed Date:  2006-10-24     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  789-91     Citation Subset:  AIM; IM    
Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use
Bone Neoplasms / complications,  secondary
Breast Neoplasms / complications*,  drug therapy
Breech Presentation
Cesarean Section
Diphosphonates / therapeutic use*
Fatal Outcome
Gestational Age
Hypercalcemia / drug therapy*,  etiology
Infant, Newborn
Infant, Premature
Obstetric Labor, Premature / prevention & control
Pre-Eclampsia / diagnosis
Pregnancy Complications, Neoplastic / diagnosis,  drug therapy*
Uterine Contraction / drug effects*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Diphosphonates; 40391-99-9/pamidronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Massive subchorionic hematoma associated with enoxaparin.
Next Document:  Extracorporeal membrane oxygenation in pregnancy.